About scynexis inc - SCYX
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
SCYX At a Glance
SCYNEXIS, Inc.
1 Evertrust Plaza
Jersey City, New Jersey 07302-6548
| Phone | 1-201-884-5485 | Revenue | 20.60M | |
| Industry | Pharmaceuticals: Major | Net Income | -8,609,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 449.947% | |
| Fiscal Year-end | 12 / 2026 | Employees | 18 | |
| View SEC Filings |
SCYX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.533 |
| Price to Book Ratio | 0.558 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.396 |
| Enterprise Value to Sales | -0.309 |
| Total Debt to Enterprise Value | -0.342 |
SCYX Efficiency
| Revenue/Employee | 1,144,500.00 |
| Income Per Employee | -478,277.778 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.275 |
SCYX Liquidity
| Current Ratio | 7.041 |
| Quick Ratio | 7.041 |
| Cash Ratio | 6.995 |
SCYX Profitability
| Gross Margin | N/A |
| Operating Margin | -78.025 |
| Pretax Margin | -41.789 |
| Net Margin | -41.789 |
| Return on Assets | -11.504 |
| Return on Equity | -16.484 |
| Return on Total Capital | -16.70 |
| Return on Invested Capital | -15.895 |
SCYX Capital Structure
| Total Debt to Total Equity | 4.405 |
| Total Debt to Total Capital | 4.219 |
| Total Debt to Total Assets | 3.685 |
| Long-Term Debt to Equity | 3.427 |
| Long-Term Debt to Total Capital | 3.282 |